Katayama, Hiroshi

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders

Cited by 258

Prognostic factors in patients receiving neoadjuvant 5‐fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015) · Oncology

Esophageal Cancer Research and TreatmentGastric Cancer Management and Outcomes

Cited by 36